Literature DB >> 31173648

Associations of pregnancy-related factors and birth characteristics with risk of endometrial cancer: A Nordic population-based case-control study.

Britton Trabert1, Rebecca Troisi1, Tom Grotmol2, Anders Ekbom3, Anders Engeland4,5, Mika Gissler6,7, Ingrid Glimelius3,8, Laura Madanat-Harjuoja9,10, Henrik Toft Sørensen11, Steinar Tretli2, Anne Gulbech Ording11, Tone Bjørge2,5.   

Abstract

Many pregnancy-related factors are associated with reduced endometrial cancer risk. However, it remains unclear whether pregnancy-related complications (e.g., hypertensive conditions) are associated with risk and whether these associations vary by endometrial cancer subtype. Thus, we evaluated the risk of endometrial cancer, overall and by subtype, in relation to pregnancy-related factors, pregnancy complications and birth characteristics. Utilizing population-based register data from four Nordic countries, we conducted a nested case-control analysis of endometrial cancer risk. We included 10,924 endometrial cancer cases and up to 10 matched controls per case. Odds ratios (ORs) with 95% confidence intervals (CIs) were derived from unconditional logistic regression models. We further evaluated associations by individual histology (i.e., endometrioid, serous, etc.) or, for rare exposures (e.g., pregnancy complications), by dualistic type (Type I [n = 10,343] and Type II [n = 581]). Preexisting and pregnancy-related hypertensive conditions were associated with increased endometrial cancer risk (OR [95% CI]: preexisting hypertension 1.88 [1.39-2.55]; gestational hypertension 1.47 [1.33-1.63]; preeclampsia 1.43 [1.30-1.58]), with consistent associations across dualistic type. Increasing number of pregnancies (≥4 vs. 1 birth: 0.64 [0.59-0.69]) and shorter time since last birth (<10 vs. ≥30 years: 0.34 [0.29-0.40]) were associated with reduced endometrial cancer risk, with consistent associations across most subtypes. Our findings support the role for both hormonal exposures and cell clearance as well as immunologic/inflammatory etiologies for endometrial cancer. This research supports studying endometrial hyperplasia, a precursor condition of endometrial cancer, in the context of pregnancy-related exposures, as this may provide insight into the mechanisms by which pregnancy affects subsequent cancer risk. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  Nordic countries; endometrial cancer; hypertension; preeclampsia; pregnancy timing

Mesh:

Year:  2019        PMID: 31173648      PMCID: PMC6898733          DOI: 10.1002/ijc.32494

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.316


  30 in total

1.  Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness.

Authors:  Inger Kristin Larsen; Milada Småstuen; Tom Børge Johannesen; Frøydis Langmark; Donald Maxwell Parkin; Freddie Bray; Bjørn Møller
Journal:  Eur J Cancer       Date:  2008-12-16       Impact factor: 9.162

2.  Hysterectomies in Finland in 1990-2012: comparison of outcomes between trainees and specialists.

Authors:  Ewa Jokinen; Tea Brummer; Jyrki Jalkanen; Jaana Fraser; Anna-Mari Heikkinen; Juha Mäkinen; Jari Sjöberg; Eija Tomàs; Tomi S Mikkola; Päivi Härkki
Journal:  Acta Obstet Gynecol Scand       Date:  2015-05-07       Impact factor: 3.636

3.  Validity of the diagnosis of pre-eclampsia in the Medical Birth Registry of Norway.

Authors:  Liv C V Thomsen; Kari Klungsøyr; Linda T Roten; Christian Tappert; Elisabeth Araya; Gunhild Baerheim; Kjersti Tollaksen; Mona H Fenstad; Ferenc Macsali; Rigmor Austgulen; Line Bjørge
Journal:  Acta Obstet Gynecol Scand       Date:  2013-05-29       Impact factor: 3.636

Review 4.  Androgens and endometrium: New insights and new targets.

Authors:  Ioannis Simitsidellis; Philippa T K Saunders; Douglas A Gibson
Journal:  Mol Cell Endocrinol       Date:  2017-09-15       Impact factor: 4.102

5.  Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.

Authors:  Britton Trabert; Ronald C Eldridge; Ruth M Pfeiffer; Meredith S Shiels; Troy J Kemp; Chantal Guillemette; Patricia Hartge; Mark E Sherman; Louise A Brinton; Amanda Black; Anil K Chaturvedi; Allan Hildesheim; Sonja I Berndt; Mahboobeh Safaeian; Ligia Pinto; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2016-11-07       Impact factor: 7.396

6.  Preeclampsia and subsequent risk of cancer: update from the Jerusalem Perinatal Study.

Authors:  Ronit Calderon-Margalit; Yechiel Friedlander; Rivka Yanetz; Lisa Deutsch; Mary C Perrin; Karine Kleinhaus; Efrat Tiram; Susan Harlap; Ora Paltiel
Journal:  Am J Obstet Gynecol       Date:  2008-09-25       Impact factor: 8.661

7.  Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium.

Authors:  Veronica Wendy Setiawan; Malcolm C Pike; Stalo Karageorgi; Sandra L Deming; Kristin Anderson; Leslie Bernstein; Louise A Brinton; Hui Cai; James R Cerhan; Wendy Cozen; Chu Chen; Jennifer Doherty; Jo L Freudenheim; Marc T Goodman; Susan E Hankinson; James V Lacey; Xiaolin Liang; Jolanta Lissowska; Lingeng Lu; Galina Lurie; Thomas Mack; Rayna K Matsuno; Susan McCann; Kirsten B Moysich; Sara H Olson; Radhai Rastogi; Timothy R Rebbeck; Harvey Risch; Kim Robien; Catherine Schairer; Xiao-Ou Shu; Amanda B Spurdle; Brian L Strom; Pamela J Thompson; Giske Ursin; Penelope M Webb; Noel S Weiss; Nicolas Wentzensen; Yong-Bing Xiang; Hannah P Yang; Herbert Yu; Pamela L Horn-Ross; Immaculata De Vivo
Journal:  Am J Epidemiol       Date:  2012-07-23       Impact factor: 4.897

8.  Endometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP Diet and Health Study.

Authors:  Hannah P Yang; Nicolas Wentzensen; Britton Trabert; Gretchen L Gierach; Ashley S Felix; Marc J Gunter; Albert Hollenbeck; Yikyung Park; Mark E Sherman; Louise A Brinton
Journal:  Am J Epidemiol       Date:  2012-11-21       Impact factor: 4.897

9.  Reproductive history and risk of colorectal adenocarcinoma in parous women: a Nordic population-based case-control study.

Authors:  Tone Bjørge; Mika Gissler; Anne Gulbech Ording; Anders Engeland; Ingrid Glimelius; Maarit Leinonen; Henrik Toft Sørensen; Steinar Tretli; Anders Ekbom; Rebecca Troisi; Tom Grotmol
Journal:  Br J Cancer       Date:  2016-10-04       Impact factor: 7.640

Review 10.  The Danish National Patient Registry: a review of content, data quality, and research potential.

Authors:  Morten Schmidt; Sigrun Alba Johannesdottir Schmidt; Jakob Lynge Sandegaard; Vera Ehrenstein; Lars Pedersen; Henrik Toft Sørensen
Journal:  Clin Epidemiol       Date:  2015-11-17       Impact factor: 4.790

View more
  4 in total

Review 1.  Understanding How Pregnancy Protects Against Ovarian and Endometrial Cancer Development: Fetal Antigens May Be Involved.

Authors:  Claudia Main; Xinyue Chen; Min Zhao; Lawrence W Chamley; Qi Chen
Journal:  Endocrinology       Date:  2022-10-11       Impact factor: 5.051

2.  Complications of Pregnancy and the Risk of Developing Endometrial or Ovarian Cancer: A Case-Control Study.

Authors:  Yang Liu; Xingyu Chen; Jiayi Sheng; Xinyi Sun; George Qiaoqi Chen; Min Zhao; Qi Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-30       Impact factor: 5.555

3.  Increased Risk of Hospitalization for Pancreatic Cancer in the First 8 Years after a Gestational Diabetes Mellitus regardless of Subsequent Type 2 Diabetes: A Nationwide Population-Based Study.

Authors:  Julien Simon; Karine Goueslard; Patrick Arveux; Sonia Bechraoui-Quantin; Jean-Michel Petit; Catherine Quantin
Journal:  Cancers (Basel)       Date:  2021-01-15       Impact factor: 6.639

4.  Assessment of All-Cause Cancer Incidence Among Individuals With Preeclampsia or Eclampsia During First Pregnancy.

Authors:  Chris Serrand; Thibault Mura; Pascale Fabbro-Peray; Gilles Seni; Ève Mousty; Thierry Boudemaghe; Jean-Christophe Gris
Journal:  JAMA Netw Open       Date:  2021-06-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.